CGRP-monoclonal antibodies in Japan: insights from an online survey of physician members of the Japanese headache society

ConclusionsMost of the respondents recommended CGRPmAbs to patients with  ≥ 2 preventive failures, followed by ≥ 1. The MMD threshold ranged mostly from ≥ 4 to ≥ 10. The concern for costs was raised as a major limiting factor for prescribing CGRPmAbs.
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research